What are the benefits of VEMLIDY? A closer look at chronic hepatitis B treatment
•
4 min read
According to the World Health Organization, over 290 million people worldwide are living with chronic hepatitis B (HBV), a potentially life-threatening liver infection. For those with compensated liver disease, VEMLIDY (tenofovir alafenamide, or TAF) offers a targeted and highly effective treatment option, with several key benefits, particularly in comparison to older-generation antivirals.
